紫杉醇联合西妥昔单抗治疗头颈部鳞状细胞癌的疗效和安全性。
Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma.
机构信息
Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
出版信息
In Vivo. 2021 Mar-Apr;35(2):1253-1259. doi: 10.21873/invivo.12376.
Abstract
BACKGROUND/AIM: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated.
PATIENTS AND METHODS
In this retrospective study, paclitaxel (80 mg/m) and cetuximab (400 mg/m loading dose followed by 250 mg/m weekly) were administered in 28-day cycles on days 1, 8, and 15.
RESULTS
Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 12.5 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients.
CONCLUSION
Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN.
摘要
背景/目的：对于复发性/转移性头颈部鳞状细胞癌（R/M SCCHN），含有铂类抗癌药物和免疫检查点抑制剂的常用方案对于铂类不耐受的患者来说并不实用。本文旨在评估紫杉醇和西妥昔单抗联合治疗 R/M SCCHN 的疗效和安全性。
患者与方法
在这项回顾性研究中，患者在 28 天的周期中接受紫杉醇（80mg/m）和西妥昔单抗（首剂量 400mg/m，随后每周 250mg/m）治疗，于第 1、8 和 15 天给药。
结果
共 38 例患者接受了治疗。一线治疗的总缓解率和疾病控制率分别为 43%和 79%，二线及以后治疗的总缓解率和疾病控制率分别为 20%和 90%。中位无进展生存期和总生存期分别为 5.3 个月和 12.5 个月。所有不良事件均可管理，包括 8-13%的患者出现 3/4 级中性粒细胞减少和贫血。
结论
紫杉醇和西妥昔单抗联合治疗可能适用于治疗 R/M SCCHN。
相似文献
1
Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma.紫杉醇联合西妥昔单抗治疗头颈部鳞状细胞癌的疗效和安全性。
In Vivo. 2021 Mar-Apr;35(2):1253-1259. doi: 10.21873/invivo.12376.
2
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).紫杉醇、卡铂和西妥昔单抗联合治疗作为复发性和/或转移性头颈部鳞状细胞癌（CSPOR-HN02）一线治疗的 II 期临床试验。
Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040.
3
Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.西妥昔单抗联合顺铂与紫杉醇单独或联合治疗头颈部鳞状细胞癌患者的疗效和安全性：一项随机试验。
Cancer Control. 2021 Jan-Dec;28:1073274821997444. doi: 10.1177/1073274821997444.
4
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.紫杉醇联合每两周 cetuximab 治疗复发或转移性头颈部癌患者的 II 期试验，这些患者之前接受过铂类化疗和抗 PD-1 抗体治疗。
ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3.
5
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.西妥昔单抗联合紫杉醇或紫杉醇单药治疗 EXTREME 后进展的复发性或转移性头颈部鳞状细胞癌患者。
Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25.
6
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.中国复发性和/或转移性头颈部鳞状细胞癌患者一线化疗联合西妥昔单抗治疗：随机III期CHANGE-2试验的疗效和安全性结果
Eur J Cancer. 2021 Oct;156:35-45. doi: 10.1016/j.ejca.2021.06.039. Epub 2021 Aug 18.
7
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.一项关于西妥昔单抗联合顺铂加或不加紫杉醇用于治疗复发性和/或转移性头颈部鳞状细胞癌患者一线治疗的随机、2 期研究。
Ann Oncol. 2017 Nov 1;28(11):2820-2826. doi: 10.1093/annonc/mdx439.
8
Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.头颈部癌症患者接受免疫检查点抑制剂治疗后采用西妥昔单抗为基础的挽救化疗的安全性和疗效。
Oncologist. 2021 Jun;26(6):e1018-e1035. doi: 10.1002/onco.13754. Epub 2021 Apr 8.
9
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.免疫检查点抑制剂治疗复发或转移性头颈部鳞状细胞癌进展后西妥昔单抗和紫杉醇的临床结局。
Medicina (Kaunas). 2021 Oct 23;57(11):1151. doi: 10.3390/medicina57111151.
10
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.西妥昔单抗、多西他赛和顺铂作为复发性或转移性头颈部鳞状细胞癌患者的一线治疗：一项多中心、II 期 GORTEC 研究。
Ann Oncol. 2015 Sep;26(9):1941-1947. doi: 10.1093/annonc/mdv268. Epub 2015 Jun 24.
引用本文的文献
1
Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.联合阳性评分和顺铂敏感性是复发性转移性头颈部鳞状细胞癌对纳武利尤单抗治疗反应的预后因素。
Clin Med Insights Oncol. 2024 Oct 16;18:11795549241290030. doi: 10.1177/11795549241290030. eCollection 2024.
2
Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.探索联合靶向表皮生长因子受体（EGFR）和纺锤体组装检查点通路在口腔癌中的治疗意义
Pharmaceutics. 2024 Sep 11;16(9):1196. doi: 10.3390/pharmaceutics16091196.
3
Molecular Classification of HNSCC Based on Inflammatory Response-Related Genes - Integrated Single-Cell and Bulk RNA-Seq Analysis.基于炎症反应相关基因的头颈部鳞状细胞癌分子分类——单细胞和批量RNA测序综合分析
J Inflamm Res. 2024 Sep 16;17:6469-6484. doi: 10.2147/JIR.S473823. eCollection 2024.
4
Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.在复发或转移性头颈部鳞状细胞癌中，继免疫检查点抑制剂治疗后采用紫杉醇联合西妥昔单抗进行化疗。
Front Oncol. 2023 Nov 21;13:1221352. doi: 10.3389/fonc.2023.1221352. eCollection 2023.
5
Evaluation of microstructure, dissolution rate, and oral bioavailability of paclitaxel poloxamer 188 solid dispersion.紫杉醇聚氧乙烯-聚氧丙烯嵌段共聚物固体分散体的微结构、溶出速率和口服生物利用度评价。
Drug Deliv Transl Res. 2024 Feb;14(2):329-341. doi: 10.1007/s13346-023-01400-0. Epub 2023 Aug 14.
6
Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.含氟尿嘧啶、顺铂和西妥昔单抗的诱导化疗治疗晚期头颈部鳞状细胞癌。
In Vivo. 2023 May-Jun;37(3):1275-1280. doi: 10.21873/invivo.13205.
7
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan.免疫检查点抑制剂在日本真实世界环境下治疗鼻咽癌的疗效。
In Vivo. 2023 Mar-Apr;37(2):747-755. doi: 10.21873/invivo.13137.
8
Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.紫杉醇和西妥昔单抗治疗复发/转移性头颈部鳞状细胞癌的真实世界数据
Cancer Diagn Progn. 2023 Mar 3;3(2):264-271. doi: 10.21873/cdp.10211. eCollection 2023 Mar-Apr.
9
Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells.表皮生长因子受体（EGFR）通路药物对头颈部癌干细胞的治疗效果。
Am J Cancer Res. 2022 Sep 15;12(9):4196-4210. eCollection 2022.
10
Cisplatin Carboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma.顺铂、卡铂和紫杉醇在局部晚期头颈部鳞状细胞癌放化疗中的应用。
In Vivo. 2022 Mar-Apr;36(2):821-832. doi: 10.21873/invivo.12769.
本文引用的文献
1
Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.纳武利尤单抗治疗复发或转移性头颈部癌后的挽救化疗。
Anticancer Res. 2020 Sep;40(9):5277-5283. doi: 10.21873/anticanres.14532.
2
Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan.真实世界中 EXTREME 方案作为复发性/转移性头颈部鳞状细胞癌一线治疗的疗效：日本多中心回顾性队列研究。
Anticancer Res. 2019 Dec;39(12):6819-6827. doi: 10.21873/anticanres.13898.
3
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
4
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.针对复发和/或转移性头颈部鳞状细胞癌患者在免疫检查点抑制剂治疗进展后的挽救性化疗的反应。
Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28.
5
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.纳武利尤单抗治疗复发和/或转移性头颈部鳞状细胞癌后化疗的疗效
Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23.
6
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.铂类化疗联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌的临床疗效：铂敏感与铂耐药患者的比较
Acta Otolaryngol. 2019 Feb;139(2):201-205. doi: 10.1080/00016489.2018.1551623. Epub 2019 Feb 22.
7
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.紫杉醇联合西妥昔单抗作为铂类同步放化疗难治性头颈部鳞状细胞癌患者的一线化疗方案
Front Oncol. 2018 Aug 27;8:339. doi: 10.3389/fonc.2018.00339. eCollection 2018.
8
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.每周紫杉醇和西妥昔单抗与 EXTREME 方案治疗复发性/转移性鳞状细胞头颈部癌的比较。
Oral Oncol. 2017 Oct;73:21-26. doi: 10.1016/j.oraloncology.2017.07.022. Epub 2017 Aug 5.
9
Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.每周一次紫杉醇联合西妥昔单抗化疗在未经选择的复发/转移性头颈部鳞状细胞癌患者中的疗效：预后因素
Clin Transl Oncol. 2017 Jun;19(6):769-776. doi: 10.1007/s12094-016-1604-z. Epub 2017 Jan 24.
10
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.西妥昔单抗与紫杉醇联合治疗头颈部鳞状细胞癌的预后预测因素
Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.
Zotero 插件